Sequential versus simultaneous combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 infection in vitro

Journal of Infectious Diseases

Volumn 176, Issue 2, 1997, Pages 510-514

  Oh, Myoung Don ^a,b   Merrill, Debra P ^a   Sutton, Lorraine ^a   Hirsch, Martin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; SAQUINAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0030877112     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517277     Document Type: Article

References (15)

1. Mazzulli T, Rusconi S, Merrill DP, et al. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother 1994;38:656-61.
2. Yarchoan R, Lietzau JA, Nguyen BY, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994;169:9-17.
3. Kojima E, Shirasaka T, Anderson BD, et al. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis 1995;171:1152-8.
4. deJong MD, Loewenthal M, Boucher CAB, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994; 169:1346-50.
5. + cell line H9 [letter]. AIDS Res Human Retroviruses 1989; 5:253-5.
6. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-αA inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 1991;164:646-55.
7. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1095-101.
8. Lennette EH. General principles underlying laboratory diagnosis of viral and rickettsial infections. In: Lennette EH, Schmidt NJ, eds. Diagnostic procedures for viral and rickettsial diseases. 3rd ed. New York: American Public Health Association, 1964:45-8.
9. Chou T. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou T, Rideout D, eds. Synergism and antagonism in chemotherapy. San Diego: Academic Press, 1991:61-98.
10. Johnson VA, Barlow MA, Merrill DP, et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-αA. J Infect Dis 1990;161: 1059-67.
11. Threlkeld SC, Hirsch MS. Antiretroviral therapy. Med Clin North Am 1996;80:1263-82.
12. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-9.
13. Smith MS, Brian EL, Pagano JS. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol 1987;61:3769-73.
14. Loveday C, Kaye S, Tenant-Flowers M, et al. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995;345:820-4.
15. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.